Market access in the German speaking markets

Pharma Market Access Insights - from Mtech Access

Here we explore market access challenges in Germany, Austria and Switzerland. Clare Foy (Global Market Access Director – Mtech Access) speaks to Dr Stefan Walzer (CEO, President & Founder at MArS Market Access & Pricing Strategy GmbH) about the challenges and opportunities for reimbursement in the German-speaking markets.
Clare and Stefan discuss:
- Preparing for access to Switzerland – a European market outside the EU
- Pricing strategy and HTA decision-making in Austria under the new Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA)
- Launching in Germany – is this still one of the most attractive European markets?
- The Financial Stabilisation Act in Germany – what this means for drug pricing
Learn more at: https://mtechaccess.co.uk/market-acce...
This episode was first broadcast as a live webinar in July 2023.

Subscribe to our newsletter to hear more news, insights and events from Mtech Access.

Κεφάλαια

1. Welcome and introductions (00:00:00)

2. Differences in stakeholders and reimbursement processes (00:02:25)

3. Market access landscape in Switzerland (00:04:59)

4. Market access and pricing in Austria (00:15:37)

5. Market access in Germany (00:21:10)

6. Changes in Germany since the Financial Stabilisation Act (00:31:03)

7. Pricing guardrails and the cap on the revenue for orphan drugs (00:38:40)

8. Price negotiations and the price volume agreement (00:44:27)

9. Impact on Pharma's global pricing strategy (00:47:58)